NCT02277717 - First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

October 31, 2019

Conditions

Solid Tumors

Interventions

DRUG

SYD985 (trastuzumab vc-seco-DUBA)

IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.

Trial Locations (15)

UZ, Antwerp

Institut Jules Bordet, Brussels

UZ, Ghent

NKI-AvL, Amsterdam

UMC, Groningen

Radboud UMC, Nijmegen

UMC, Rotterdam

Institut Catala d'Oncologia, Barcelona

Vall d'Hebron University Hospital, Barcelona

START Madrid-CIOCC, Madrid

START Madrid-FJD, Madrid

Beatson Institute for Cancer Research, Glasgow

The Christie NHS Foundation Trust, Manchester

Churchill Hospital, Oxford

Royal Marsden / Institute of Cancer Research, Sutton